VHL PAT82B10AT Antibody

The Von Hippel-Lindau (VHL) protein is a crucial tumor suppressor encoded by the VHL gene. Mutations in this gene are associated with Von Hippel-Lindau disease, a hereditary condition characterized by the formation of tumors and cysts in various organs, including the brain, spinal cord, kidneys, and pancreas .

The VHL protein plays a significant role in the regulation of hypoxia-inducible factors (HIFs), which are transcription factors that respond to changes in oxygen levels in the cellular environment. Under normal oxygen conditions, the VHL protein targets HIFs for ubiquitination and subsequent degradation, thus preventing the activation of hypoxia-responsive genes . However, under low oxygen conditions (hypoxia), HIFs escape degradation and activate the transcription of genes involved in angiogenesis, metabolism, and survival .

Clone PAT82B10AT is a monoclonal antibody specifically developed to target the VHL protein in human cells. This antibody is derived from mouse and is used in various research applications, including Western blotting, ELISA, and immunocytochemistry/immunofluorescence . The specificity and high affinity of Clone PAT82B10AT make it a valuable tool for studying the VHL protein’s function and its role in disease mechanisms.

The use of Clone PAT82B10AT in research has provided significant insights into the molecular mechanisms underlying VHL disease and other related conditions. By targeting the VHL protein, researchers can investigate its interactions with other cellular proteins, its role in the ubiquitination pathway, and its impact on cellular responses to hypoxia . This antibody has also been instrumental in identifying potential therapeutic targets and developing strategies for treating VHL-associated tumors.